Hardesty, J. E., Wahlang, B., Prough, R. A., Head, K. Z., Wilkey, D., Merchant, M., Shi, H., Jin, J., & Cave, M. C. (2021). Effect of Epidermal Growth Factor Treatment and Polychlorinated Biphenyl Exposure in a Dietary-Exposure Mouse Model of Steatohepatitis. *Environmental Health Perspectives*, *129*(3). https://doi.org/10.1289/EHP8222

Definitions

- **Polychlorinated Biphenyls (PCBs)**: Toxic industrial chemicals that persist in the environment and can cause various health issues.
- **Epidermal Growth Factor (EGF)**: A protein that stimulates cell growth and differentiation by binding to its receptor, EGFR.
- **Nonalcoholic Steatohepatitis (NASH)**: A severe form of nonalcoholic fatty liver disease, characterized by liver inflammation and damage caused by fat buildup.

Key Findings

- EGF treatment reduced liver inflammation and fibrosis caused by PCB exposure in mice.
- EGF increased markers of liver health but also caused higher blood sugar levels and lower insulin sensitivity.
- PCB exposure led to significant liver damage and inflammation, which EGF could partially counteract.

Introduction

This study investigates whether Epidermal Growth Factor (EGF) can reduce liver damage caused by Polychlorinated Biphenyls (PCBs) in mice. PCBs are environmental pollutants known to cause severe liver conditions, including nonalcoholic steatohepatitis (NASH). The research aims to see if EGF can improve liver health by enhancing EGFR signaling, which is disrupted by PCBs.

Main Content

Background

PCBs are harmful chemicals that can cause liver diseases like NASH. They disrupt normal liver functions by interfering with EGFR signaling. EGF is known to promote liver health, so this study tests if EGF can mitigate the liver damage caused by PCBs.

Methods

- **Subjects**: Male C57BL/6 mice were used.
- **Diet and Treatment**: Mice were fed a high-fat diet (42% milk fat) and exposed to PCBs (Aroclor 1260) or a control vehicle for 12 weeks.

- **EGF Administration**: EGF or a control vehicle was given daily for 10 days starting at week 10.
- **Assessments**:
    - Liver and metabolic phenotyping.
    - Histological analysis of liver tissue.
    - Measurement of liver inflammation and fibrosis markers.
    - Blood tests for glucose levels and insulin sensitivity.

Results

- **EGFR Signaling**: EGF-treated mice showed increased EGFR signaling.
- **Liver Health**: EGF reduced liver inflammation and fibrosis in PCB-exposed mice.
- **Blood Sugar**: EGF-treated mice had higher blood sugar levels and reduced insulin sensitivity.
- **Gene Expression**: EGF affected the expression of various genes involved in liver metabolism and health.

Conclusion

The study demonstrates that EGF can reduce some of the liver damage caused by PCBs in mice by improving EGFR signaling. However, EGF also caused higher blood sugar levels and reduced insulin sensitivity, indicating potential side effects. More research is needed to fully understand the benefits and risks of EGF treatment for PCB-related liver damage.

Word Count: 384